119 related articles for article (PubMed ID: 22123157)
1. Anaphylactic reaction after injection of glatiramer acetate (Copaxone®) in patients with relapsing-remitting multiple sclerosis.
Baumgartner A; Stich O; Rauer S
Eur Neurol; 2011; 66(6):368-70. PubMed ID: 22123157
[No Abstract] [Full Text] [Related]
2. Contact dermatitis induced by glatiramer acetate.
Haltmeier S; Yildiz M; Müller S; Anliker MD; Heinzerling L
Mult Scler; 2011 Nov; 17(11):1390-2. PubMed ID: 21729979
[TBL] [Abstract][Full Text] [Related]
3. Lobular panniculitis at the site of glatiramer acetate injections for the treatment of relapsing-remitting multiple sclerosis. A report of two cases.
Ball NJ; Cowan BJ; Moore GR; Hashimoto SA
J Cutan Pathol; 2008 Apr; 35(4):407-10. PubMed ID: 18333902
[TBL] [Abstract][Full Text] [Related]
4. Progressive lipoatrophy after cessation of glatiramer acetate injections: a case report.
Hashimoto S; Ball Nj; Tremlett H
Mult Scler; 2009 Apr; 15(4):521-2. PubMed ID: 19091880
[No Abstract] [Full Text] [Related]
5. Erythema nodosum and glatiramer acetate treatment in relapsing-remitting multiple sclerosis.
Thouvenot E; Hillaire-Buys D; Bos-Thompson MA; Rigau V; Durand L; Guillot B; Camu W
Mult Scler; 2007 Aug; 13(7):941-4. PubMed ID: 17881403
[TBL] [Abstract][Full Text] [Related]
6. Glatiramer acetate for treatment of relapsing-remitting multiple sclerosis.
Johnson KP
Expert Rev Neurother; 2012 Apr; 12(4):371-84. PubMed ID: 22449210
[TBL] [Abstract][Full Text] [Related]
7. Long-term follow up of glatiramer acetate compassionate use in Belgium.
Sindic CJ; Seeldrayers P; Vande Gaer L; De Smet E; Nagels G; De Deyn PP; Medaer R; Guillaume D; D'Hooghe MB; Deville MC; Decoo D; Sadzot B; Van Landegem W; Strauven T; Pepin J; Merckx H; Caekebeke J; van der Tool MA
Acta Neurol Belg; 2005 Jun; 105(2):81-5. PubMed ID: 16076061
[TBL] [Abstract][Full Text] [Related]
8. Effects of glatiramer acetate on spasticity in previously interferon-beta-treated and treatment-naive patients with relapsing-remitting multiple sclerosis: a prospective, nonrandomized, open-label, uncontrolled, observational pilot study.
Meca-Lallana JE; de Mingo-Casado P; Amorin-Díaz M; Martínez-Navarro ML; Barreiro AF
Clin Ther; 2010 Jun; 32(6):1061-6. PubMed ID: 20637960
[TBL] [Abstract][Full Text] [Related]
9. Glatiramer acetate in combination with minocycline in patients with relapsing--remitting multiple sclerosis: results of a Canadian, multicenter, double-blind, placebo-controlled trial.
Metz LM; Li D; Traboulsee A; Myles ML; Duquette P; Godin J; Constantin M; Yong VW;
Mult Scler; 2009 Oct; 15(10):1183-94. PubMed ID: 19776092
[TBL] [Abstract][Full Text] [Related]
10. Phase III dose-comparison study of glatiramer acetate for multiple sclerosis.
Comi G; Cohen JA; Arnold DL; Wynn D; Filippi M;
Ann Neurol; 2011 Jan; 69(1):75-82. PubMed ID: 21280077
[TBL] [Abstract][Full Text] [Related]
11. Localized panniculitis and subsequent lipoatrophy with subcutaneous glatiramer acetate (Copaxone) injection for the treatment of multiple sclerosis.
Soós N; Shakery K; Mrowietz U
Am J Clin Dermatol; 2004; 5(5):357-9. PubMed ID: 15554737
[TBL] [Abstract][Full Text] [Related]
12. Severe anaphylactic reaction to glatiramer acetate with specific IgE.
Rauschka H; Farina C; Sator P; Gudek S; Breier F; Schmidbauer M
Neurology; 2005 Apr; 64(8):1481-2. PubMed ID: 15851756
[No Abstract] [Full Text] [Related]
13. Necrotizing skin lesion and radial nerve palsy in a patient treated with glatiramer acetate.
Carotenuto A; Iodice R; Barbato F; Orefice NS; Orefice G
J Neurol Sci; 2013 Aug; 331(1-2):172-3. PubMed ID: 23778027
[TBL] [Abstract][Full Text] [Related]
14. Glatiramer acetate treatment in patients with childhood and juvenile onset multiple sclerosis.
Kornek B; Bernert G; Balassy C; Geldner J; Prayer D; Feucht M
Neuropediatrics; 2003 Jun; 34(3):120-6. PubMed ID: 12910434
[TBL] [Abstract][Full Text] [Related]
15. [Nicolau syndrome after administration of glatiramer acetate].
Pulido Pérez A; Parra Blanco V; Suárez Fernández R
Neurologia; 2013 Sep; 28(7):448-9. PubMed ID: 22698594
[No Abstract] [Full Text] [Related]
16. Contribution of endermology to improving indurations and panniculitis/lipoatrophy at glatiramer acetate injection site.
Rubio Fernández D; Rodríguez Del Canto C; Marcos Galán V; Falcón N; Edreira H; Sevane Fernández L; Francoli Martínez P; Sánchez-De la Rosa R
Adv Ther; 2012 Mar; 29(3):267-75. PubMed ID: 22382874
[TBL] [Abstract][Full Text] [Related]
17. [Glatiramer acetate in interferon beta non respondent relapsing-remitting multiple sclerosis].
Oreja-Guevara C; Bermejo PE; Miralles A; Gabaldón L; Aguilar MJ; Díez-Tejedor E
Neurologia; 2009 Sep; 24(7):435-8. PubMed ID: 19921551
[TBL] [Abstract][Full Text] [Related]
18. Glatiramer acetate for multiple sclerosis.
Drug Ther Bull; 2001 Jun; 39(6):41-3. PubMed ID: 11432030
[TBL] [Abstract][Full Text] [Related]
19. Glatiramer: new preparation. No place in multiple sclerosis.
Prescrire Int; 2004 Feb; 13(69):10-2. PubMed ID: 15055208
[TBL] [Abstract][Full Text] [Related]
20. Glatiramer acetate-associated, CD30+, primary, cutaneous, anaplastic large-cell lymphoma.
Madray MM; Greene JF; Butler DF
Arch Neurol; 2008 Oct; 65(10):1378-9. PubMed ID: 18852356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
